Suven Life Sciences Limited has informed the Exchange regarding Board meeting held on July 03, 2025 - Allotment of 6,40,02,999 warrants convertible into equity shares.
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.4 pts more than Nifty Microcap 250 and 1.7 pts more than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Suven Life Sciences has allotted 6.40 crore convertible warrants to 23 allottees at Rs. 134 per warrant on a preferential basis, following shareholder approval at the EGM on June 5, 2025. The total potential value of the issue works out to roughly Rs. 857.6 crore, of which the company has already received 25% upfront (Rs. 214.41 crore) as required under SEBI rules. The promoter group entity, Jasti Property and Equity Holdings (trustee of the Jasti Family Trust), received the largest share at about 3.18 crore warrants (~49.6% of the total). Among the non-promoter allottees, Quant Mutual Fund (47 lakh warrants), 3P India Equity Fund, Abakkus Diversified Alpha Fund, and several HNIs have also subscribed. Since these are warrants and not equity shares, there is no immediate change in the paid-up capital of the company.
Strong promoter commitment and a healthy mix of institutional and HNI investors signal confidence in the company. However, shareholders should note potential future dilution once these warrants are exercised into equity shares.